VALIDATION OF STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF ENALAPRIL MALEATE IN TABLET FORMULATIONS

MANINDRA MOHAN¹, S. ZAFAR HAIDER⁴, ANKUR K. ANAND², AMIT K. SRIVASTVA²

¹Centre for Aromatic Plants (CAP), Selaqui Dehradun, Planet Herbs Lifesciences (P) Ltd., Selaqui 248197, Dehradun (Uttarakhand) India.
Email: manmicro59@gmail.com

ABSTRACT

The aim of present work was to validate the high performance liquid chromatographic method for the analysis of enalapril maleate in pharmaceutical formulation. The method validation of enalapril maleate was performed by using Hypersil MOS, 5μ (250 mm x 4.6 mm) as stationary phase with mobile phase consists of buffer solution and Acetonitrile (40:60) at flow rate of 1.5 ml/min. The column temperature and wavelength were monitored at 65°C and 215 nm, respectively. The injection volume was 50 μl for the run time 2.5 min. The validated method found within limits in all validated parameters and is quick and reliable for quantitative analysis as well as quality control of enalapril maleate in pharmaceutical formulation.

Keywords: Stability indicating, HPLC, Enalapril maleate, Hypersil MOS, Specificity, Precision, Accuracy.

INTRODUCTION

Enalapril maleate (1-[N-(s)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline 1-ethyl ester maleate) is a potent angiotensinconverting (ACE) enzyme inhibitor¹. It is a pro-drug without direct biological activity which is rapidly absorbed after oral administration and de-esterified in vivo to its active metabolite enalaprilat diketopiperazine derivative (DKP) and has little pharmacologic activity until hydrolyzed in the liver to enalaprilat₂. Enalapril maleate is a pro-drug which is rapidly absorbed after oral administration and de-esterified in vivo to its active metabolite enalaprilat diketopiperazine derivative (DKP) and has little pharmacologic activity until hydrolyzed in the liver to enalaprilat. Enalapril maleate is a pro-drug that is rapidly absorbed after oral administration and de-esterified in vivo to its active metabolite enalaprilat diketopiperazine derivative (DKP) and has little pharmacologic activity until hydrolyzed in the liver to enalaprilat. Enalapril maleate is a pro-drug that is rapidly absorbed after oral administration and de-esterified in vivo to its active metabolite enalaprilat diketopiperazine derivative (DKP) and has little pharmacologic activity until hydrolyzed in the liver to enalaprilat. Enalapril maleate is a pro-drug that is rapidly absorbed after oral administration and de-esterified in vivo to its active metabolite enalaprilat diketopiperazine derivative (DKP) and has little pharmacologic activity until hydrolyzed in the liver to enalaprilat.

High performance liquid chromatography (HPLC) has been the only practical technique for the determination of enalapril in pharmaceutical dosage forms without interference from degradation products. However, severe conditions that shorten column life, such as low pH of the solvent and high column temperature, are required for acceptable peak shape, because enalapril exists as two rotational isomers owing to the alanyl-proline moiety in its structure. The aim of present work is to validate the method for assay of enalapril maleate in enalapril maleate formulation to show specificity, degradation studies, linearity response, precision, accuracy and stability in analytical solution.

MATERIALS AND METHODS

Material and reagents

The required materials and regents were Monobasic Potassium phosphate (AR grade), Water (Milli Q grade), Acetonitrile (HPLC grade), Orthophosphoric acid (85% w/w; AR grade), Enalapril maleate tablets of strength 5 mg/tablet, Placebo for enalapril tablets of strength 5 mg/tablet, Enalapril maleate working standard of percentage potency 99.55% w/w.

Instrumentation and software

A gradient HPLC (Waters 600 Controller) equipped with online degasser, Waters 600 pump, Manual injector system, Photodiode Array Detector (PAD, Waters 2996), C18 column (Hypersil MOS, size: 250 mm x 4.6 mm particle size 5μm) and Empower 2 software on computer (Window XP Professional 2002 professional); Vacuum filtration assembly (Pall corporation); Ultrasonic cleaner (Toschon Model: SW 7); Analytical balance (Mettler Toledo, Model: XS 204)

Chromatographic conditions

The chromatographic column used was C18 Hypersil MOS, particle size 5μm (250 mm x 4.6 mm) of Thermo scientific make. The mobile phase consists of buffer solution and Acetonitrile (40:60). The flow rate of the mobile phase was kept at 1.5 ml/min and the column temperature was maintained at 65°C and the chromatograms were monitored at a wavelength of 215 nm. The injection volume was 50 μl for the run time 2.5 min.

Preparation of solvents and solutions

Buffer Solution preparation

136 mg of monobasic Potassium phosphate dissolved in 800 mL of water, adjusted with Phosphoric acid to a pH of 2.0, and then diluted with water to 1000 mL, and mixed.

Mobile phase preparation

A filtered and degased mixture of buffer solution and Acetonitrile (40:60) was prepared.

Diluents preparation

Buffer solution was used as diluents.

Preparation of Placebo solution

A weighed portion of placebo powder, equivalent to 50 mg of Enalapril maleate in Enalapril maleate tablet was transferred into a 250 ml volumetric flask. About 150 ml buffer solution added and sonicated for 15 min, and maintained the volume upto the mark, mixed and filtered through 0.45μ or finer porosity membrane filter.
Standard solution preparation
50 mg of enalapril maleate working standard was transferred into a 250 ml volumetric flask, about 150 ml of buffer solution added and sonicated to dissolve. Maintained the volume upto the mark, mixed and filtered through 0.45μ or finer porosity membrane filter.

Sample solution preparation
20 tablets were weighed and finely powdered. An accurately weighed and finely powdered tablet blend, equivalent to about 50 mg of enalapril maleate was transferred into a 250 ml volumetric flask. About 150 ml of buffer solution was added and sonicated for 15 min. maintained the volume upto the mark with buffer solution, mixed properly and filtered through 0.45μ or of finer porosity membrane filter, discarding the first few ml portion of the filtrate. The final solution contains about 200 μg/ml of enalapril maleate.

Procedure
Equal volumes of the standard solution and the sample solution were separately injected in duplicate. Record the chromatograms and measure the peak area count of the enalapril peak with the aid of an integrator.

Specificity
The placebo solution as well as sample solution of enalapril maleate tablets of strength 5 mg were separately transferred to three volumetric flasks of 250 ml. About 150 ml of buffer solution was added and sonicated for 15 min. maintained the volume upto the mark with buffer solution, mixed properly and filtered through 0.45μ or of finer porosity membrane filter.

Degradation Studies
An accelerated degradation study was carried out on the enalapril maleate tablets according to the following conditions. The results are shown in Table 1.

- **a) Hydrolytic and Oxidative Degradation**
  Accurately weighed and finely powdered tablet blend, equivalent to 50 mg of enalapril maleate were separately transferred in three volumetric flasks of 250 ml. The samples were treated separately with 0.1 N HCl, 0.01 N NaOH and 1% v/v H2O2 and analyzed. Samples treated with 0.1N HCl, 0.01 N NaOH and 10% v/v H2O2 were analyzed again after heating for 2 h on water bath maintained at 60°C.

- **b) Thermal Degradation**
  The sample was subjected to accelerated thermal degradation by keeping at 80°C for 24 h. The sample was further analysed by the proposed method.

- **c) Photolytic Degradation**
  Photolytic degradation study was carried out by exposing the sample to light (1900 Lux) for 24 h and followed by analysis as per the proposed method.

Using the peak purity test, the purity of enalapril peak was checked at every stage of above study. The peak purity plots show that the enalapril peak is homogenous and there are no coeluting peaks indicating that method is stability indicating and specific.

### Table 1: Degradation Studies

<table>
<thead>
<tr>
<th>Mode of Degradation</th>
<th>Time (h)</th>
<th>Assay (mg/tablet)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td></td>
<td>4.94</td>
</tr>
<tr>
<td>0.1 N HCl (60°C)</td>
<td>0 h</td>
<td>4.96</td>
</tr>
<tr>
<td></td>
<td>2 h</td>
<td>5.03</td>
</tr>
<tr>
<td>0.1 N NaOH (60°C)</td>
<td>0 h</td>
<td>5.19</td>
</tr>
<tr>
<td></td>
<td>2 h</td>
<td>5.12</td>
</tr>
<tr>
<td>1 % v/v H2O2 (60°C)</td>
<td>0 h</td>
<td>5.24</td>
</tr>
<tr>
<td></td>
<td>2 h</td>
<td>4.26</td>
</tr>
<tr>
<td>Photolytic (1900 Lux)</td>
<td>24 h</td>
<td>4.54</td>
</tr>
<tr>
<td>Thermal (60°C)</td>
<td>24 h</td>
<td>2.70</td>
</tr>
</tbody>
</table>

### Linearity of response
The linearity of response for enalapril maleate was determined and found to be linear in the range of 150 to 250μg/ml. Results are shown in Table 2.

### Table 2: Linearity of Response - Regression Output

<table>
<thead>
<tr>
<th>Constant</th>
<th>100378.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Std Err of Y Est</td>
<td>23325.93</td>
</tr>
<tr>
<td>R Squared</td>
<td>0.999201</td>
</tr>
<tr>
<td>No. of observations</td>
<td>7</td>
</tr>
<tr>
<td>Degree of Freedom</td>
<td>5</td>
</tr>
<tr>
<td>X Coefficient (s)</td>
<td>19660.63</td>
</tr>
<tr>
<td>Std Err of Coef.</td>
<td>248.6853</td>
</tr>
</tbody>
</table>

### Precision

#### System Precision
Six replicate injections of enalapril maleate standard solution were made into the HPLC system as per proposed method. The results along with the percentage RSD of area counts for enalapril maleate indicated an acceptable level of precision (0.82) for the analytical system (Acceptance Criteria: RSD ≤2).

#### Method Precision
Six replicate samples of a single batch of enalapril maleate tablets were prepared and analysed by the proposed HPLC method. The calculated percentage RSD of assay indicated that the method has an acceptable level of precision (0.27) for the proposed method. (Acceptance Criteria % RSD ≤0.7).

### Accuracy
A known amount of Enalapril maleate tablets placebo powder was taken and spiked with enalapril maleate working standard at three different levels in triplicate. The samples were analysed as per the proposed method. The results indicate that the method has an acceptable level recovery. (Acceptance criteria: % Recovery should be in the range 90% - 110%). Results are shown in Table 3.

### Table 3: Accuracy

<table>
<thead>
<tr>
<th>Recovery Level</th>
<th>Amount added (mg)</th>
<th>Amount recovered (mg)</th>
<th>% Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>I – A</td>
<td>42.110</td>
<td>41.089</td>
<td>97.58</td>
</tr>
<tr>
<td>I – B</td>
<td>39.322</td>
<td>39.747</td>
<td>101.08</td>
</tr>
<tr>
<td>I – C</td>
<td>40.517</td>
<td>40.202</td>
<td>99.22</td>
</tr>
<tr>
<td>II – A</td>
<td>49.875</td>
<td>49.330</td>
<td>98.91</td>
</tr>
<tr>
<td>II – B</td>
<td>49.277</td>
<td>49.269</td>
<td>99.98</td>
</tr>
<tr>
<td>II – C</td>
<td>50.771</td>
<td>50.573</td>
<td>99.61</td>
</tr>
<tr>
<td>III – A</td>
<td>58.635</td>
<td>58.059</td>
<td>99.02</td>
</tr>
<tr>
<td>III – B</td>
<td>60.029</td>
<td>59.561</td>
<td>97.55</td>
</tr>
<tr>
<td>III – C</td>
<td>62.517</td>
<td>61.208</td>
<td>98.91</td>
</tr>
</tbody>
</table>

Mean: 98.98 S.D. 1.174 % RSD 1.19
Stability in analytical solution

A sample solution of Enalapril maleate tablet powder was prepared and kept at room temperature (25°C). Sample solution was analysed at different time intervals. As the % RSD up to 1601 min. is 0.217 which is less than the % RSD for method precision (0.27), it was concluded that sample solution is stable in analytical solution for about 26 h.

System suitability data

Standard solution was injected during the validation studies and the column efficiency and tailing factor for enalapril peak was calculated. The results met within acceptance criteria of system suitability.

RESULTS AND DISCUSSION

The peak purity data indicates that the peak is homogenous and it has no co-eluting peaks with the main peak indicating specificity of the method, as well as at the time of method validation studies the degradation study, linearity of response, precision, accuracy, stability in analytical solution and system suitability acceptance criteria were also found within limits.

Therefore, the proposed validated method is quick and reliable and can be used for routine quantitative analysis as well as quality control of Enalapril maleate in pharmaceutical formulation.

Fig. 1: A Typical HPLC chromatogram of Enalapril maleate standard

Fig. 2: A Typical HPLC chromatogram of Enalapril maleate in Sample

ACKNOWLEDGEMENT

Authors are thankful to Dr. Harish C. Andola, Centre for Aromatic Plants (CAP), Selaqui, Dehradun for his support and help during the course of study.

REFERENCES


